Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARGARET: Dexamethasone Premedication for Preventing ILD in Breast Cancer Patients on T-DXd
NCT07828054Phase 3Not yet recruiting
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Dec 2026
- Primary completion
- Dec 2030
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in interstitial lung disease (ILD) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Cumulative incidence of Interstitial Lung Disease > Grade 1 at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dexamethasone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07828054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828054.